Asian Journal of Case Reports in Medicine and Health

Vanishing Bile Duct Syndrome Mini-review and Case Report of This Rare Disease

Cohen Ramon *

Internal Department B, Kaplan Medical Center, Rehovot, Israel.

Attali Malka

Internal Department B, Kaplan Medical Center, Hebrew University Medical School, Rehovot, Israel.

*Author to whom correspondence should be addressed.

---

Abstract

Aim: Vanishing bile duct syndrome (VBDS) is a rare condition that affects the liver and bile ducts. It is characterized by the progressive destruction or loss of bile ducts in the liver. The causes of vanishing bile duct syndrome are not fully understood, but it can occur as a result of a variety of factors, including infections, autoimmune disorders, certain medications, and genetic conditions.

Presentation: we report a case of VBDS after a treatment with Bortezumid and Linelomide. We explain the pathophysiology and the actual knowledge of the treatment.

Conclusion: Plasmapheresis not seems to replace immunosuppressive treatment if there are not improvement and support that the use of plasmapheresis in isolated VBDS is limited.

Keywords: Dili, Drug induce liver injury, VBDS, vanishing bile duct syndrome, multiple myeloma

---

---

---

References

Greca RD, Cunha-Silva M, Costa LBE, Costa JGF, Mazo DFC, Sevá-Pereira T, Nascimento MMC, Pereira IE, Oliveira FC, Faria GAS, Neto FLP, Almeida JRS. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case. Ann Hepatol. 2020;19(1):107-112.

DOI: 10.1016/j.aohep.2019.06.010. Epub 2019 Aug 19. PMID: 31537508.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Vanishing Bile Duct Syndrome. [Updated 2019 Dec 11]. Available:https://www.ncbi.nlm.nih.gov/books/NBK548715/

Suk KT, Kim DJ. Drug-induced liver injury: Present and future. Clin Mol Hepatol. 2012;18(3):249-57.

DOI: 10.3350/cmh.2012.18.3.249. Epub 2012 Sep 25. PMID: 23091804; PMCID: PMC3467427.

Bessone F, Hernández N, Tanno M, Roma MG. Drug-induced vanishing bile duct syndrome: from pathogenesis to diagnosis and therapeutics. Semin Liver Dis. 2021;41(3):331-348. DOI: 10.1055/s-0041-1729972.

Epub 2021 Jun 15. Erratum in: Semin Liver Dis. 2021 Jun 29;: PMID: 34130334.

Scoazec JY. Drug-induced bile duct injury: New agents, new mechanisms. Curr Opin Gastroenterol. 2022;38(2):83-88. DOI: 10.1097/MOG.0000000000000813. PMID: 34931623.

Bonkovsky HL, Kleiner DE, Gu J, Odin JA, Russo MW, Navarro VM, Fontana RJ, Ghabril MS, Barnhart H, Hoofnagle JH; U.S. Drug Induced Liver Injury Network Investigators. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017; 65(4):1267-1277.

DOI: 10.1002/hep.28967. Epub 2017 Feb 7. PMID: 27981596; PMCID: PMC5360519.

Eiswerth MJ, Heckroth MA, Ismail A, et al. Infliximab-induced vanishing bile duct syndrome. Cureus. 2022;14(2):e21940. DOI:10.7759/cureus.21940

Mizuno F, Imai N, Yasuda K, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M, Kawashima H. Successful treatment with steroids in a patient with vanishing bile duct syndrome and acute tubular necrosis. Intern Med; 2023. DOI: 10.2169/internalmedicine.1826-23. Epub ahead of print. PMID: 37164665.

White JC, Appleman S. Infliximab/ plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis. Pediatrics. 2014;134(4):e1194-8. DOI: 10.1542/peds.2013-2239. Epub 2014 Sep 22.

PMID: 25246624; PMCID: PMC4535040.